liver cancer

Showing 11 posts of 11 posts found.


Transgene terminates oncolytic IO combo trial in advanced liver cancer

August 8, 2019
Research and Development Cancer, Transgene, clinical trials, liver cancer, pharma

Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …

Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer

April 8, 2019
Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma

Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …


Keytruda falls short at Phase 3 in advanced liver cancer

February 20, 2019
Research and Development Cancer, MSD, keytruda, liver cancer, pharma

MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …

NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer

December 19, 2018
Research and Development, Sales and Marketing Lenvima, NICE, UK, liver cancer, pharma

UK drug watchdog NICE has revealed that it has recommended Eisai’s Lenvima (lenvatinib) for use on the NHS in England …


Eisai’s Lenvima wins over NICE in liver cancer in just three months

November 9, 2018
Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma

Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …


Ipsen reveals positive Phase 3 data of Cabometyx in liver cancer

July 5, 2018
Research and Development Cabometyx, Cancer, ipsen, liver cancer, pharma

French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase …


Research unveils new drug targets for more effective treatment of liver disease

August 22, 2017
Manufacturing and Production, Research and Development life sciences, liver, liver cancer, liver disease, pharma, pharmaceuticals

Researchers from KTH The Royal Institute of Technology and Gothenburg University have identified new drug targets in the treatment of …

Bayer’s liver cancer drug availability spreads to UK with NICE approval

August 10, 2017
Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical

NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …


FDA approves first new drug for liver cancer in decade

April 28, 2017
Medical Communications, Sales and Marketing Bayer, Stivarga, hepatocellular carcinoma, liver cancer

The FDA has announced that it has approved the first new treatment for hepatocellular carcinoma (HCC), a type of liver …


Bayer says its Stivarga improved overall survival in liver cancer in late-stage trials

June 30, 2016
Research and Development, Sales and Marketing Bayer, Stivarga, drug trial, liver cancer

German pharma and crop sciences giant Bayer (ETR: BAYN) said late-stage trials for its drug to treat liver cancer showed a …

Bayer’s liver cancer drug meets primary endpoint in late stage trial

May 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial

Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …

Latest content